Phase 2 HIV and AIDS Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 65 years old, of any sex
- People who have been diagnosed with HIV-1
- People who have been on continuous HIV treatment for at least 12 months, with no breaks longer than 14 days in a row, and who have been on a stable treatment plan for at least 4 weeks that does not include a specific class of HIV drugs called NNRTIs or any long-acting HIV medications
- People whose HIV has been undetectable in their blood for the past 12 months (one or two low-level blips in results may still be acceptable — confirm with trial site)
- People whose lowest-ever recorded immune cell count (CD4+ T cells) was above 300 cells/mm³
- People whose most recent immune cell count is at or above 500 cells/mm³
- People who have a full record of their HIV treatment history available, and for whom an effective backup treatment plan could be put together if needed
- People who are willing to temporarily pause their HIV treatment as part of the study
Who may not be able to join:
- People who are pregnant, breastfeeding, or not willing to use contraception during the study
- People whose current HIV treatment includes a long-acting HIV drug or an NNRTI that could remain active in the body for up to one year after stopping treatment
- People whose current HIV treatment includes drugs known as protease inhibitors and/or AZT, as these may increase the risk of side effects from one of the study drugs
- People who have ever had a cancer linked to HIV, such as Kaposi's sarcoma or any type of lymphoma, or cancers caused by viruses
- People who have a current or past hepatitis B infection, based on specific blood test results (confirm with trial site)
- People who currently have an active hepatitis C infection
- People who have active or latent (dormant) tuberculosis
- People who have long-term liver disease
- People who have heart or blood vessel disease that is currently active and not well managed
- People who are not willing to either abstain from sex or use barrier protection (such as condoms) during the period when HIV treatment is paused
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Steven Deeks, MD, University of California, San Francisco
Phone: 415-476-4082
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of participants reporting a new Grade 3 or greater adverse event that is definitely, probably, or possibly related to study treatment within 1 year of product administration.; Number of participants achieving post-treatment control within 36 weeks of product administration.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.